Trial Profile
The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: a Single-arm Phase II Clinical Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Adenocarcinoma; Medullary thyroid cancer; Thyroid cancer
- Focus Therapeutic Use
- Acronyms AHNATHY
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 30 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 18 Mar 2020 New trial record